Zydus Lifesciences Share Price in Focus After USFDA Approves Menopause Treatment

Written by: Team Angel OneUpdated on: 22 Oct 2026, 4:13 pm IST

Zydus Lifesciences has received final USFDA approval for a hormone replacement therapy used to treat menopause symptoms.

Zydus Lifesciences announced on October 21, 2026, that the US Food and Drug Administration had approved its generic version of the Estradiol and Levonorgestrel Transdermal System.

Approval Comes with Potential 180-Day Exclusivity

The product has been designated a Competitive Generic Therapy (CGT) by the USFDA. It may qualify for 180 days of exclusivity under the CGT pathway, subject to US regulatory requirements. Any applicable exclusivity period would begin when the product is first commercially marketed.

Product to Be Made in Gujarat

The treatment is used to manage moderate to severe menopause symptoms and may also help prevent osteoporosis in postmenopausal women. Zydus will manufacture the product at its Moraiya facility near Ahmedabad, Gujarat.

The product had annual US sales of approximately $45.7 million as of August 2026, according to IQVIA data cited by the company. As of September 30, 2026, Zydus had received 458 approvals and filed 516 abbreviated new drug applications (ANDAs) with the USFDA.

As of October 21, 2026, at 12:26 PM, Zydus Lifesciences share price was trading at ₹1,107.80 per share, reflecting a 0.55% change from the previous trading session.

Also Check: Pharmaceuticals Stocks

Conclusion

The USFDA approval adds another product to Zydus Lifesciences' US generics portfolio. The potential 180-day exclusivity could give the company a period of limited generic competition, subject to the applicable conditions.

Turn insights into action - Open Free Demat Account with Angel One and start investing instantly.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Oct 21, 2026, 2:22 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More